comprehensive -WSS

comprehensive

author：knowledge 2025-09-06 01:59:45 - browse：696

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

WSS

Health tech investors get more selective as pandemic boom fades

Readers respond to H5N1 and livestock movements, and more

Arc Institute generative AI designs new CRISPR systems

Health tech investors get more selective as pandemic boom fades

Roche drug slashes death risk in early

Why a market frenzy over new weight loss drugs defies logic

hotspot

comprehensive

knowledge

How one medical school became remarkably diverse

When prostate cancer spreads, where it goes matters

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

What does generative AI mean for health care? We asked experts

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Medicare details structure of new drug price negotiation program

Readers respond to H5N1 and livestock movements, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

hotspot

NVIDIA and Google execs on the future of AI and drug discovery

Readout LOUD podcast: Live from the 2023 STAT Summit

Why a market frenzy over new weight loss drugs defies logic

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

How AI can help patients find reliable information about doctors

Big Tobacco's 'harm reduction': Is it for real, or a sham?

focus

hotspot

focus

focus